What Is Well-being in Psoriasis?

June 24, 2024

Spotlight on Psychodermatology: Yale Study Links PsO to OCD

June 19, 2024

EULAR News: IL-12/23 and IL-23 Blockers May Prevent Progression to PsA in PsO Patients

June 12, 2024

MoonLake Immunotherapeutics Receives Regulatory Greenlights for Phase 3 Program of Sonelokimab in PsA

June 10, 2024

What’s Inside IPC’s New Consensus Statement on GPP? TDD Talks to IPC’s Chief Medical Officer Dr. Peter van de Kerkhof

June 6, 2024

Zai Lab Initiates Global Phase 2 Clinical Trial of Topical 1L-17 Blocker in Chronic Plaque Psoriasis

May 22, 2024

Elucidating the Role of HIF-1-alpha in Psoriasis

May 21, 2024

Meet the ASA 2024 Research Achievement Award & Inaugural Founders Award Winners

May 20, 2024

Recludix Pharma’s REX-7117 Shows Promise in Preclinical Studies of Th17-mediated Skin Inflammation

May 17, 2024

Four-Year Data: Sotyktu Demonstrates Durable Response Rates, Consistent Safety in Moderate-to-Severe Plaque PsO

May 17, 2024

AnaptysBio, Inc.’s Imsidolimab Performs Well in Phase 3 GPP Study

May 9, 2024

LEO’s Enstilar Performs Well in Phase 3 Study of Adults With Stable Plaque Psoriasis in China

May 7, 2024